• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Recent Advances in the Study of 3-(4-Ethoxycarbonylphenyl)isonicotinic Acid (CAS: 1261929-79-6)

3-(4-Ethoxycarbonylphenyl)isonicotinic acid (CAS: 1261929-79-6) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique isonicotinic acid scaffold and ethoxycarbonylphenyl moiety, has demonstrated promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and potential as a building block for more complex bioactive molecules.

Recent synthetic chemistry studies have explored novel routes for the efficient production of 3-(4-Ethoxycarbonylphenyl)isonicotinic acid. A 2023 publication in the Journal of Medicinal Chemistry reported an optimized Pd-catalyzed coupling approach that achieves yields of over 85% while maintaining excellent purity. This advancement addresses previous challenges in the large-scale synthesis of this compound, which had limited its broader application in drug discovery programs.

In terms of biological activity, preliminary screening data published in Bioorganic & Medicinal Chemistry Letters (2024) indicates that 3-(4-Ethoxycarbonylphenyl)isonicotinic acid exhibits moderate inhibitory activity against several kinase targets, particularly showing promise in the low micromolar range against certain cancer-associated kinases. These findings suggest its potential as a lead compound for further structural optimization in oncology drug development.

The compound's physicochemical properties have also been extensively characterized in recent research. A comprehensive study in the European Journal of Pharmaceutical Sciences (2023) reported its favorable solubility profile and stability under physiological conditions, making it particularly suitable for formulation development. The logP value of 2.3 ± 0.2 suggests good membrane permeability while maintaining sufficient aqueous solubility for biological testing.

Emerging applications of 3-(4-Ethoxycarbonylphenyl)isonicotinic acid extend beyond its direct biological activity. Several research groups have utilized it as a key intermediate in the synthesis of more complex drug candidates. A notable example includes its incorporation into novel PROTAC (Proteolysis Targeting Chimera) molecules, as described in a recent ACS Medicinal Chemistry Letters publication, where it served as the linker component connecting target-binding and E3 ligase-recruiting moieties.

Ongoing research is investigating the compound's potential in addressing drug resistance mechanisms. Preliminary data presented at the 2024 American Chemical Society National Meeting demonstrated that derivatives of 3-(4-Ethoxycarbonylphenyl)isonicotinic acid could modulate efflux pump activity in multidrug-resistant bacterial strains and cancer cell lines, opening new avenues for combination therapies.

Future research directions for this compound appear promising, with several pharmaceutical companies listing it in their patent applications as a core structure for new chemical entities. The versatility of its chemical structure allows for diverse modifications, making it a valuable scaffold for medicinal chemistry programs targeting various disease areas, including inflammation, infectious diseases, and metabolic disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)